Streamlining Drug Interaction Information
Author Information
Author(s): Asmar Valeria, Bergman Erik, Lindhagen Elin, Sherwood Kim, Westman Gabriel, Gaugaz Fabienne Zdenka
Primary Institution: Swedish Medical Products Agency, Uppsala, Sweden
Hypothesis
The study investigates how risks associated with transporter-mediated drug-drug interactions are reported in medicinal product information.
Conclusion
There is potential for improving the clarity and relevance of warnings in product information regarding transporter-mediated drug-drug interactions.
Supporting Evidence
- 192 out of 859 approved medicinal products had relevant SmPC text.
- Most texts were located in SmPC Section 5.2.
- BCRP had the highest number of clinically relevant interaction texts.
Takeaway
This study looked at how warnings about drug interactions are written in medicine guides, finding ways to make them clearer and more useful for doctors.
Methodology
The study screened the Summary of Product Characteristics (SmPCs) of medicinal products approved in the EU from 2012 to 2023 for warnings on specific transporters and categorized the warnings based on clinical relevance.
Limitations
The study only included products approved through the central procedure and may not represent all medicinal products.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website